Back to top
more

Zynex (ZYXI)

(Delayed Data from NSDQ)

$10.49 USD

10.49
162,008

+0.15 (1.45%)

Updated May 10, 2024 04:00 PM ET

After-Market: $10.48 -0.01 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ZYXI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Zynex Inc. [ZYXI]

Reports for Purchase

Showing records 41 - 60 ( 93 total )

Company: Zynex Inc.

Industry: Medical - Products

Record: 41

02/28/2020

Company Report

Pages: 6

4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy; Raising PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 42

02/26/2020

Company Report

Pages: 6

Blood Volume Monitor 510(k) Approval; Reiterate Buy; Raising PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 43

02/04/2020

Company Report

Pages: 5

Blood Volume Monitor European Patent Granted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 44

01/10/2020

Company Report

Pages: 5

Preliminary 4Q19 Results; Revenue and EBITDA Guidance Raised; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 45

10/30/2019

Company Report

Pages: 5

Top-Line Revenue Grows 45% YoY in 3Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 46

10/03/2019

Company Report

Pages: 6

NexWave Orders Grow 95% YoY in 3Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 47

09/23/2019

Company Report

Pages: 22

We are initiating coverage with a Buy rating and 12-month price target of $12 per share.

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 75.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 48

05/03/2019

Company Report

Pages: 4

Dropping coverage due to termination of research services

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 10.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 49

03/01/2019

Company Report

Pages: 16

Upgrading to a Buy rating from Speculative Buy and raising our 12-month price target to $8.00 per share from $6.00

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 50.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 50

11/09/2018

Company Report

Pages: 16

Maintaining Speculative Buy rating and increasing our 12-month price target to $6.00 per share from $5.50

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 50.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 51

08/16/2018

Company Report

Pages: 6

$6.75 price target for Zynex

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 52

08/08/2018

Company Report

Pages: 16

Maintaining Speculative Buy rating but reducing our 12-month price target to $5.50 per share

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 50.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 53

08/07/2018

Company Report

Pages: 10

Reported 2Q18 EPS

Provider: Consilium Global Research

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 54

05/15/2018

Company Report

Pages: 10

We believe this is exceptional as growth in this quarter is typically seasonally the lowest.

Provider: Consilium Global Research

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 55

05/15/2018

Company Report

Pages: 6

We are raising our price target and top line estimates following strong results

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 56

05/14/2018

Company Report

Pages: 15

Maintaining Speculative Buy rating and 12-month price target of $6.35 per share reflecting an increase in our 2019 EPS forecast

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 50.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 57

03/09/2018

Company Report

Pages: 16

Maintaining Speculative Buy rating

Provider: Taglich Brothers, Inc.

Analyst: HALPERN H

Price: 50.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 58

03/07/2018

Company Report

Pages: 11

reported 4Q17 EPS

Provider: Consilium Global Research

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 59

03/07/2018

Company Report

Pages: 6

We are raising our price target and estimates following strong results

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Zynex Inc.

Industry: Medical - Products

Record: 60

01/16/2018

Company Report

Pages: 6

We are raising our price target

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party